Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Apotex Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1354)
Cancellation or suspension (47)
Prescription medicine registration (18)
ARTG (8)
Australian Public Assessment Report (AusPAR) (1)
Listed medicine compliance report (1)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (4)
2023 (16)
2022 (159)
2021 (104)
2020 (216)
2019 (124)
2018 (380)
2017 (307)
2016 (37)
2015 (52)
2014 (32)

Results for "[search-keyword]"

Search

Sponsor content

1431 result(s) found, displaying 841 to 850

TERRY WHITE CHEMISTS VALSARTAN valsartan 160 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
TERRY WHITE CHEMISTS VALSARTAN valsartan 320 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GenRx Valsartan HCTZ 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
Chemmart Valsartan HCTZ 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
Terry White Chemists Valsartan HCTZ 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
Terry White Chemists Valsartan HCTZ 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
Chemmart Valsartan HCTZ 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GenRx Valsartan HCTZ 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 March 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX LAMOTRIGINE lamotrigine 25 mg Dispersible/Chewable tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 February 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX LAMOTRIGINE lamotrigine 50 mg Dispersible/Chewable tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 February 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd

Pages

First page
Previous page
…
Page 81
Page 82
Page 83
Page 84
Current page 85
Page 86
Page 87
Page 88
Page 89
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.